Drug Profile
Research programme: stem cell therapies - Healios/Sumitomo Pharma
Alternative Names: Allo iPS cell-derived retinal pigment epithelium cell therapy; Induced pluripotent stem cell (iPSC)-derived retinal pigment epithelium (RPE) cell therapy - Healios/Sumitomo Pharma; iPSC-derived RPE cell therapy - Healios/Sumitomo PharmaLatest Information Update: 28 Sep 2022
Price :
$50
*
At a glance
- Originator Dainippon Sumitomo Pharma; Healios
- Developer Healios; National Eye Institute
- Class Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Dry age-related macular degeneration; Wet age-related macular degeneration
Most Recent Events
- 28 Sep 2022 No recent reports of development identified for preclinical development in Dry age-related macular degeneration in European Union (Intraocular)
- 28 Sep 2022 No recent reports of development identified for preclinical development in Wet age-related macular degeneration in Japan (Intraocular)
- 28 Jun 2022 No recent reports of development identified for preclinical development in Dry age-related macular degeneration in USA (Intraocular)